Close Menu

NEW YORK (GenomeWeb) – Natera said today that it has struck a distribution deal with Thermo Fisher Scientific's One Lamda to co-distribute its cell-free DNA-based kidney transplant rejection test in the US.

Parisa Khosropour, president of transplant diagnostics at Thermo Fisher Scientific, said in a statement that Natera's cfDNA test "complements [its] existing transplant offerings and enables us to provide a more advanced portfolio for monitoring kidney rejection."

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.